Cipla launches Q-TIB globally, a novel fixed dose combination in a single tablet for T.B. prophylaxis in HIV
Posted on December 5,2017
Cipla Ltd have announced that it has received an approval for its product Q-TIB from World Health Organisation.
Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally.
Q-TIB will help prevent tuberculosis infection in people living with HIV. People living with HIV face a challenged immune system and are prone to opportunistic infections, which constitute the major source of premature deaths among them. As per Global TB Report, 2016, by WHO, about one million people died of AIDS-related illness. Most of them succumbed to opportunistic infections, and among them, 400,000 died of tuberculosis.